I find penny's with potential to run quick. Follow if you can keep up!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
how you like them slaps you must be glowing haha
not enough buying power = hold down ...
vfin comes out to play due to lack of ask smackage classsic everyone asked for it by not hitting 3s
correct market makers hiding all buys to stop momentum pretty smart ;)
$SPCL shaking everything they can cute
MM hiding orders this is gonna go
are you alerting this or using it as an example from the past? thx bux
Red to green coming?
gap all the way to $1.42 Shes got more IMO
Stevie! I bet he knows something big lol
.4 to 2.30 weeeeeeeeeee
circuit breaker again holy!
Maybe other people haven't read it or would like to know whats going on.... FYI I am not pumping the only thing pumping is the whales on level 2 today and the chart lol have a good one. $PPCH
I was just summarizing the amazing PR the company fed us.. sorry you don't like what the company is telling you lol
PPCH NEWS
MELBOURNE, Australia, April 19, 2016 /PRNewswire/ -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the filing of two more patent applications in the United States regarding new compositions of its lead product, PRP, for treating cancer. The inventions summarize different combinations of the two proenzymes, trypsinogen and chymotrypsinogen, which synergistically enhance their anti-cancer effects, compared to when used in a one to one ratio, or as singular agents.
The combinations are in addition to the preferred combination for PRP, and supplements the Company's patent position across a broad range of cancers.
"When confirming PRP's effectiveness across a broad range of cancers, we also confirmed a synergistic response between the two proenzymes to the majority of cancer cell lines tested," said Dr Julian Kenyon, Propanc's Chief Scientific Officer. "We also noticed that for some cancer types, more than one combination proved to be effective, which we believe is patentable.
This is extremely important, because it not only confirms the utility of our lead product, PRP, for many different cancers, but also enables us to incorporate other effective combinations as well. In total, we now have five individual patents covering PRP and also expect to file further divisional applications in various jurisdictions. We are extremely pleased with our progress as we develop a robust portfolio as leaders in the field."
"Dr Kenyon and our team of researchers have done an excellent job in continuing to grow and protect the Company's IP position," said James Nathanielsz, Propanc's Chief Executive Officer. "New, potentially patentable discoveries have also been made regarding the anti-cancer effects of proenzymes which we believe could have significant implications in the cancer treatment process. We look forward to continuing to build on this research. Furthermore, we are now preparing for what is a significant period for the Company as we turn our attention to the upcoming scientific advice meeting, preparing orphan drug designation applications and developing a strategy to engage licensing partners interested in our R&D programs, as we head towards early stage patient trials."
The Company is soon to meet with the MHRA (Medicines and Healthcare Products Regulatory Agency) to discuss formal preclinical and clinical development activities for PRP. Management also intends to apply for orphan drug designation for pancreatic and ovarian cancers in the US and EU in the near future as well, should they satisfy the necessary criteria.
The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
About Propanc:
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.
Logo - http://photos.prnewswire.com/prnh/20160112/321703LOGO
SOURCE Propanc Health Group Corporation
Related Links
http://www.propanc.com
Wow so we cured cancer and have multiple patents on them in a 20 billion dollar market.. Boom!
This is amazing this company could be the once in a lifetime kind that you buy really low and tell the grand kids about when its $50+
I think it needs to fill that gap at .3
400 000 smack! :) at .042 wow
Daily chart looks great also
Big slaps coming in!
111 million bidding 3 game on!
after 2 comes 3 :)
Thanks $CBYL still has more I believe will be on watch for tomorrow if she can get back above .82
Ya I was done after it peaked..
any other charts with that gap to fill? really liking the setups
lol Cramer pumping MTW note alert only comes out at stock highs haha
Beast mode!
Beasting! i think we have a big gap up tomorrow if we can hold this
weeee looks like beast mode!
reversal time ?
reload time first :)
weee nice open today!
Oh another lovely gap to fill nice find see you Monday :)
we are going to $1.48 + IMO :)
Lets fill that gap on the daily Clay! :)
weeee think ill hold some for monday morning gap :)
red to green weeeeeee lol
that gap at 2 is calling me lol
rockets firing red to green! weeeee
here we go?
POS shorts or a whale is trying to eat everything he can you be the judge lol
I want to see the rocket engines fire up soon!